The Phase II study on the efficacy and safety of weekly nab-paclitaxel with 3 rd line therapy or more of advanced or recurrent non-small cell lung cancer after disease progression on 2nd line therapy or more
- Conditions
- Advanced or recurrent non-small cell lung cancer
- Registration Number
- JPRN-UMIN000023763
- Lead Sponsor
- Division of Medical Oncology Department of Internal Medicine Teikyo University School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 36
Not provided
1.Patients with paclitaxel treatment history. 2.Patients with hypersensitivity to paclitaxel or preparations containing albumin. 3.Patients with active double cancer in need of treatment. However it is not excluded that carcinoma in situ that is judged to be healing by local treatment, intramucosal cancer equivalent of lesions or other cancers unlikely in need of treatment. 4.The infection requiring systemic treatment (including patient of HBs antigen-positive). 5.Serious complications (heart disease, interstitial pneumonia, uncontrolled high blood pressure or diabetes, etc.) 6.there is a possibility of pregnancy or during pregnancy or lactating women. 7.Patients with psychosis or psychotic symptoms is determined to be difficult to participants in a clinical trial. 8.Patients during systemic administration steroids therapy(oral or intravenous). 9.Patients with symptomatic brain metastases. 10.Other, cases physicians it is judged unsuitable for registration of this clinical trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Disease Control Rate
- Secondary Outcome Measures
Name Time Method Response Rate, Overall survival, Progression free survival, Time to Treatment Failure, Adverse events (adverse reactions) occurrence rate